Chemours Co
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| THE CHEMOURS COMPANY | |
| (Registrant) | |
| Date: | March 27, 2024 |
| By: | /s/ Matthew S. Abbott |
| Matthew S. Abbott | |
| Interim Chief Financial Officer and Chief Accounting Officer, and Senior Vice President, Chief Enterprise Transformation Officer | |
| (As Duly Authorized Officer and Principal Financial Officer and | |
| Principal Accounting Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated:
| Signature | Title(s) | Date | |
|---|---|---|---|
| /s/ Denise Dignam | President, Chief Executive Officer, and Director | March 27, 2024 | |
| Denise Dignam | (Principal Executive Officer) | ||
| /s/ Matthew S. Abbott | Interim Chief Financial Officer and Chief | March 27, 2024 | |
| Matthew S. Abbott | Accounting Officer, and Senior Vice President, Chief Enterprise Transformation Officer | ||
| (Principal Financial Officer and | |||
| Principal Accounting Officer) | |||
| /s/ Dawn L. Farrell | Chairperson of the Board | March 27, 2024 | |
| Dawn L. Farrell | |||
| /s/ Curtis V. Anastasio | Director | March 27, 2024 | |
| Curtis V. Anastasio | |||
| /s/ Alister Cowan | Director | March 27, 2024 | |
| Alister Cowan | |||
| /s/ Mary B. Cranston | Director | March 27, 2024 | |
| Mary B. Cranston | |||
| /s/ Pamela Fletcher | Director | March 27, 2024 | |
| Pamela Fletcher | |||
| /s/ Erin N. Kane | Director | March 27, 2024 | |
| Erin N. Kane | |||
| /s/ Sean D. Keohane | Director | March 27, 2024 | |
| Sean D. Keohane | |||
| /s/ Sandra Phillips Rogers | Director | March 27, 2024 | |
| Sandra Phillips Rogers | |||
| /s/ Guillaume Pepy | Director | March 27, 2024 | |
| Guillaume Pepy | |||
INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) | F-2 |
|---|---|
| Consolidated Statements of Operations for the years ended December 31, 2023, 2022, and 2021 | F-6 |
| Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2023, 2022, and 2021 | F-7 |
| Consolidated Balance Sheets at December 31, 2023 and 2022 | F-8 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023, 2022, and 2021 | F-9 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022, and 2021 | F-10 |
| Notes to the Consolidated Financial Statements | F-11 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.